Is I-131 Tositumomab therapeutic regimen Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use I-131 Tositumomab therapeutic regimen? Is I-131 Tositumomab therapeutic regimen safe for nursing mother and child? Does I-131 Tositumomab therapeutic regimen extracts into breast milk? Does I-131 Tositumomab therapeutic regimen has any long term or short term side effects on infants? Can I-131 Tositumomab therapeutic regimen influence milk supply or can I-131 Tositumomab therapeutic regimen decrease milk supply in lactating mothers?

Information in this record refers to the use of I-131 Tositumomab therapeutic regimen as a therapeutic agent. No information is available on the use of I-131 Tositumomab therapeutic regimen during breastfeeding. Because of the potential for serious adverse reactions in nursing infants, the manufacturer and expert opinion recommend not administering the drug in women who wish to continue breastfeeding.[1] If the drug is given, breastfeeding should be discontinued. Parents should limit close contact with their infants and small children after therapeutic I-131 Tositumomab therapeutic regimen administration. Suggested contact times by one group are 30 minutes per day or less of contact at a distance of 2 meters or less for a period of 6 to 23 days.[2] Another group suggests avoiding contact with small children at a distance of 10 cm for an average of 8.1 days (range 3.5 to 12.9 days).[3] Additionally, nursing mothers may have excessive I 131 uptake by the breasts, so they should receive potassium iodide or Lugol's solution before receiving I-131 Tositumomab therapeutic regimen to block uptake by the breasts and thyroid. Nursing mothers should not work with substances containing I 131 in their workplace.[4]